Adaptive Phage licenses phage library from Walter Reed

By The Science Advisory Board staff writers

August 31, 2021 -- Adaptive Phage Therapeutics (APT) has signed a licensing agreement with the Walter Reed Army Institute of Research (WRAIR) to gain access to its phage database.

The deal, which is synergistic with APT's ongoing partnership with the U.S. Navy, provides APT with access to the phage database of the U.S. military to treat critically ill patients. The opportunity to work with the U.S. Army's laboratory resources and research experts at WRAIR will aid in development of APT's PhageBank phage library, APT said.

It also expands the company's relationship with the U.S. Department of Defense and affirms its commitment to providing antimicrobial resistance treatment options to war fighters and veterans, according to APT.

Adaptive Phage Therapeutics gets $40.8M to advance its phage therapies
Adaptive Phage Therapeutics has closed $40.8 million in financing to accelerate the clinical development of its PhageBank phage therapies.
Adaptive Phage gets $10M to develop COVID-19 vaccine
Adaptive Phage Therapeutics has been awarded $9.8 million by the U.S. Department of Defense to develop multiple high-priority bacteriophage-based...

Copyright © 2021

Last Updated ka 8/31/2021 4:34:24 PM